Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) was the recipient of a large increase in short interest during the month of June. As of June 30th, there was short interest totalling 4,762,400 shares, an increase of 8.9% from the May 30th total of 4,371,200 shares. Based on an average trading volume of 1,050,000 shares, the days-to-cover ratio is currently 4.5 days. Approximately 14.6% of the company’s stock are sold short.

BHVN opened at $45.72 on Tuesday. Biohaven Pharmaceutical has a 1-year low of $29.17 and a 1-year high of $67.86. The firm has a fifty day simple moving average of $50.49. The company has a market cap of $1.89 billion, a PE ratio of -7.43 and a beta of 0.26.

Biohaven Pharmaceutical (NYSE:BHVN) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($1.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.50) by $0.09. During the same period in the prior year, the firm posted ($2.32) earnings per share. On average, sell-side analysts predict that Biohaven Pharmaceutical will post -6.32 EPS for the current year.

In related news, CFO James Engelhart acquired 2,500 shares of the company’s stock in a transaction dated Thursday, June 27th. The shares were bought at an average price of $43.05 per share, for a total transaction of $107,625.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director John W. Childs acquired 10,000 shares of the company’s stock in a transaction dated Wednesday, June 26th. The shares were bought at an average price of $40.37 per share, for a total transaction of $403,700.00. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 17,500 shares of company stock valued at $712,425. Insiders own 23.90% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of BHVN. Flinton Capital Management LLC bought a new position in Biohaven Pharmaceutical during the 4th quarter worth $42,000. Neuburgh Advisers LLC bought a new position in Biohaven Pharmaceutical during the 4th quarter worth $52,000. Manchester Capital Management LLC bought a new position in Biohaven Pharmaceutical during the 1st quarter worth $52,000. NumerixS Investment Technologies Inc increased its position in Biohaven Pharmaceutical by 333.3% during the 1st quarter. NumerixS Investment Technologies Inc now owns 2,600 shares of the company’s stock worth $134,000 after buying an additional 2,000 shares during the period. Finally, Legal & General Group Plc increased its position in Biohaven Pharmaceutical by 14.1% during the 4th quarter. Legal & General Group Plc now owns 5,284 shares of the company’s stock worth $196,000 after buying an additional 652 shares during the period. Institutional investors and hedge funds own 90.38% of the company’s stock.

A number of equities research analysts have recently issued reports on BHVN shares. Morgan Stanley set a $61.00 price objective on Walgreens Boots Alliance and gave the stock a “hold” rating in a research note on Tuesday, May 14th. ValuEngine upgraded WPP from a “sell” rating to a “hold” rating in a research note on Wednesday, June 19th. Goldman Sachs Group set a €75.30 ($87.56) price objective on Stroeer SE & Co KGaA and gave the stock a “buy” rating in a research note on Monday, May 6th. Zacks Investment Research upgraded DLH from a “sell” rating to a “hold” rating in a research note on Tuesday, July 9th. Finally, Svb Leerink upped their price objective on Biohaven Pharmaceutical from $50.00 to $67.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 23rd. Three investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $70.18.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Recommended Story: Institutional Investors

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.